Zelira Therapeutics Limited (ZLD.AX)
AUD 0.62
(1.64%)
AUD 0.62
(1.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 5.06 Million AUD | 1738.55% |
| 2023 | 291.69 Thousand AUD | 112.99% |
| 2022 | -2.24 Million AUD | 49.2% |
| 2021 | -4.42 Million AUD | -315.14% |
| 2020 | -1.06 Million AUD | 65.35% |
| 2019 | -3.07 Million AUD | 45.95% |
| 2018 | -5.68 Million AUD | 27.73% |
| 2017 | -7.86 Million AUD | -933.19% |
| 2016 | 944.3 Thousand AUD | 390.92% |
| 2015 | -324.59 Thousand AUD | 45.68% |
| 2014 | -597.53 Thousand AUD | 38.35% |
| 2013 | -969.3 Thousand AUD | 24.19% |
| 2012 | -1.27 Million AUD | -62.26% |
| 2011 | -787.96 Thousand AUD | -129.49% |
| 2010 | -343.35 Thousand AUD | 82.02% |
| 2009 | -1.9 Million AUD | -74.58% |
| 2008 | -1.09 Million AUD | -135.41% |
| 2007 | 3.08 Million AUD | 196.22% |
| 2006 | 1.04 Million AUD | 171.42% |
| 2005 | -1.45 Million AUD | 32.16% |
| 2004 | -2.15 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | 5.06 Million AUD | 0.0% |
| 2024 Q2 | 1.66 Million AUD | 0.0% |
| 2024 FY | 3.24 Million AUD | 1013.98% |
| 2023 FY | 291.69 Thousand AUD | 112.99% |
| 2023 Q2 | 360.4 Thousand AUD | 0.0% |
| 2023 Q4 | 291.69 Thousand AUD | 0.0% |
| 2022 Q2 | -7.07 Million AUD | 0.0% |
| 2022 Q4 | -2.24 Million AUD | 0.0% |
| 2022 FY | -2.24 Million AUD | 49.2% |
| 2021 Q2 | -8.11 Million AUD | 0.0% |
| 2021 Q4 | -4.42 Million AUD | 0.0% |
| 2021 FY | -4.42 Million AUD | -315.14% |
| 2020 Q2 | -1.16 Million AUD | 0.0% |
| 2020 FY | -1.06 Million AUD | 65.35% |
| 2020 Q4 | -1.06 Million AUD | 0.0% |
| 2019 FY | -3.07 Million AUD | 45.95% |
| 2019 Q2 | -4.41 Million AUD | 0.0% |
| 2019 Q4 | -3.07 Million AUD | 0.0% |
| 2018 Q4 | -5.68 Million AUD | 0.0% |
| 2018 FY | -5.68 Million AUD | 27.73% |
| 2018 Q2 | -6.61 Million AUD | 0.0% |
| 2017 FY | -7.86 Million AUD | -933.19% |
| 2017 Q4 | -7.86 Million AUD | 0.0% |
| 2017 Q2 | -3.59 Million AUD | 0.0% |
| 2016 Q4 | 944.3 Thousand AUD | 0.0% |
| 2016 FY | 944.3 Thousand AUD | 390.92% |
| 2016 Q2 | -159.6 Thousand AUD | 0.0% |
| 2015 Q4 | -324.59 Thousand AUD | 0.0% |
| 2015 FY | -324.59 Thousand AUD | 45.68% |
| 2014 Q4 | -597.53 Thousand AUD | 0.0% |
| 2014 FY | -597.53 Thousand AUD | 38.35% |
| 2013 Q4 | -969.3 Thousand AUD | 0.0% |
| 2013 FY | -969.3 Thousand AUD | 24.19% |
| 2012 FY | -1.27 Million AUD | -62.26% |
| 2012 Q4 | -1.27 Million AUD | 0.0% |
| 2011 Q4 | -787.96 Thousand AUD | 0.0% |
| 2011 FY | -787.96 Thousand AUD | -129.49% |
| 2010 Q4 | -343.35 Thousand AUD | 0.0% |
| 2010 FY | -343.35 Thousand AUD | 82.02% |
| 2009 Q4 | -1.9 Million AUD | 0.0% |
| 2009 FY | -1.9 Million AUD | -74.58% |
| 2008 FY | -1.09 Million AUD | -135.41% |
| 2008 Q4 | -1.09 Million AUD | 0.0% |
| 2007 FY | 3.08 Million AUD | 196.22% |
| 2007 Q4 | 3.08 Million AUD | 0.0% |
| 2006 FY | 1.04 Million AUD | 171.42% |
| 2006 Q4 | 1.04 Million AUD | 0.0% |
| 2005 FY | -1.45 Million AUD | 32.16% |
| 2005 Q4 | -1.45 Million AUD | 0.0% |
| 2004 FY | -2.15 Million AUD | 0.0% |
| 2004 Q4 | -2.15 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 126.813% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 615.965% |
| Biome Australia Limited | -1.56 Million AUD | 424.245% |
| Patrys Limited | -2.24 Million AUD | 326.153% |
| Orthocell Limited | -19.92 Million AUD | 125.432% |
| Imugene Limited | -91.56 Million AUD | 105.534% |
| Noxopharm Limited | -2.31 Million AUD | 318.426% |
| PYC Therapeutics Limited | -65.76 Million AUD | 107.706% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 265.979% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 149.862% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 180.13% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 181.66% |
| CSL Limited | 15.76 Billion AUD | 99.968% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 139.855% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | 814.153% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 102.769% |
| Starpharma Holdings Limited | -19.83 Million AUD | 125.551% |
| Nanollose Limited | -96.22 Thousand AUD | 5366.127% |
| Memphasys Limited | 4.13 Million AUD | -22.536% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 184.104% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 202.285% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 377.877% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 106.389% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 509.181% |
| Race Oncology Limited | -17.18 Million AUD | 129.48% |
| Nyrada Inc. | -4.76 Million AUD | 206.247% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 104.79% |
| Dimerix Limited | -21.99 Million AUD | 123.042% |
| PharmAust Limited | -9.71 Million AUD | 152.165% |
| Immutep Limited | -122.18 Million AUD | 104.147% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 103.712% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 140.604% |
| BTC Health Limited | -2.02 Million AUD | 350.591% |
| Acrux Limited | -1.45 Million AUD | 447.554% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 129.644% |
| Biotron Limited | -386.06 Thousand AUD | 1412.549% |
| Tissue Repair Ltd | -16.44 Million AUD | 130.821% |
| AdAlta Limited | -845.17 Thousand AUD | 699.561% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 127.28% |
| Hexima Limited | -2.22 Million AUD | 327.621% |
| AnteoTech Limited | -5 Million AUD | 201.316% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 128.822% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 249.209% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 195.085% |
| Actinogen Medical Limited | -9.13 Million AUD | 155.492% |
| Immuron Limited | -11.48 Million AUD | 144.126% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 131.845% |